Director of Clinical Operations (Neuroscience)

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.

In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs currently enrolling:  ARV-102 for the treatment of patients with neurodegenerative disorders,ARV-393 for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma and potentially other lymphomas, and ARV-806, a KRAS G12D PROTAC for the treatment patients with solid tumors with KRAS G12D mutations.  

On August 8^th 2025, the U.S. Food and Drug Administration (FDA)  accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant.

In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024.

#TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say.

For more information, please visit www.arvinas.com. 

• →12+ years of clinical operations experience, with significant hands-on leadership of early-phase clinical trials, including Phase I/II studies.
• →Deep expertise in neuroscience clinical trials, particularly in neurodegenerative diseases (e.g., PD, PSP, SBMA, ALS).
• →Demonstrated success in CRO oversight and vendor management, with a strong ability to drive performance, accountability, and quality.
• →Proven experience advancing programs from preclinical/IND-enabling through early clinical development.
• →5+ years of people management experience, with the ability to build and lead high-performing teams.
• →Strong understanding of GCP, ICH guidelines, and global regulatory requirements.
• →Experience in biotech or fast-paced clinical-stage environments, with the ability to operate with agility and accountability.
• →Excellent strategic thinking, problem-solving, and risk management skills.
• →Strong communication and stakeholder management skills, with the ability to influence at senior levels.
• →Demonstrated ability to manage budgets, timelines, and competing priorities across multiple programs.
• →Experience with INDs and early clinical development is highly preferred.
• →Clinical pharmacology and/or dose-escalation study experience is desirable.
• →Willingness to travel as needed.
• →Arvinas will not be providing VISA sponsorship for this position. You must have the ability to work without a need for current or future VISA sponsorship.
• →The duties of this role are generally conducted in a combination of company office and home office environments. Employees must be able, with or without an accommodation use a computer; engage in communications via phone, video, and electronic messaging; engage in problem solving, analysis and dialogue; collaborate with others; maintain general availability during standard business hours.

• Experience in Parkinson’s Disease, PSP, SBMA, ALS, or related neurodegenerative disorders.
• Experience with rare disease trials, including patient recruitment challenges and innovative trial designs.
• Familiarity with decentralized trial elements and digital health technologies.
• Experience with patient registries and natural history studies.
• Prior experience building or scaling clinical operations infrastructure in a growing biotech.

• Bachelor’s degree in Life Sciences, Pharmacy, or related field required; advanced degree preferred.

Arvinas is proud to offer a competitive package of base and incentive compensation as well as a comprehensive benefits program designed to support the health, wellness and financial security of our employees and their families. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, and much more. To learn more about Arvinas, please visit www.arvinas.com

Arvinas is an equal opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identify, national origin, disability or protected veteran status.